The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer
Open accessAbstract
Patients with metastatic breast cancer have a five-year survival rate of 27% compared to 98% for localized cancer, and the presence of even a few cancer cells in lymph nodes, known as isolated tumor cells or nanometastases, significantly increases the risk of relapse in the absence of aggressive treatment. Therefore, diagnosis and treatment of lymphatic metastases in early breast cancer plays an important role in patient survival. Here, we demonstrate the first description of a delivery system for localized doxorubicin chemotherapy to the breast tissue. The hyaluronan-doxorubicin nanoconjugate exhibits a sustained release characteristic in vitro and in vivo in the breast tissues of rodents bearing human breast cancer xenografts. In addition, the conjugate reduces dose-limiting cardiac toxicity with minimal toxicity observed in normal tissues. Finally, the conjugate dramatically inhibits breast cancer progression in vivo, leading to an increased survival rate. Thus, localized chemotherapy to the breast lymphatics with a nanocarrier may represent an improved strategy for treatment of early stage breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective
Götte, M., & Yip, G. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1464 · Cited by 340
Cited by
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Hyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 596
Hollow luminescent carbon dots for drug delivery
Wang, Q., Huang, X., Long, Y., Wang, X., Zhang, H., Zhu, R., Liang, L., Teng, P., & Zheng, H. (2013) · Carbon · doi:10.1016/j.carbon.2013.03.009 · Cited by 493
Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics
Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., Watanabe, H., Franchi, M., Baud, S., Brézillon, S., Götte, M., Passi, A., Vigetti, D., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00354 · Cited by 367
Recent advances in natural polymer-based drug delivery systems
Tong, X., Pan, W., Su, T., Zhang, M., Dong, W., & Qi, X. (2020) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2020.104501 · Cited by 349
Metadata
- Authors
- Cai, S., Thati, S., Bagby, T. R., Diab, H.-M., Davies, N. M., Cohen, M. S., & Forrest, M. L.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2010-09-01
- Volume
- 146
- Issue
- 2
- Pages
- 212-218
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2168015221
- Cited by
- 163
- References
- 2
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. https://app.cochat.ai/papers/10.1016/j.jconrel.2010.04.006
- The paper
- Cai, S., Thati, S., Bagby, T. R., Diab, H.-M., Davies, N. M., Cohen, M. S., & Forrest, M. L. (2010). Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2010.04.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.